In summary, MET amplification in NSCLC cells and CD73 expression in MET-amplified EGFR-TKI-resistant cells can significantly reduce STING levels and anti-tumor T cell infiltration, thereby compromising the efficacy of ICB therapy for NSCLC. The gene discussed is MET; the disease is neoplasm.